Implications of the ADVANCE study for clinical practice

Area of Science:

• Cardiology
• Endocrinology
• Clinical Trials

Background:

• Blood pressure is a key factor in macro- and microvascular complications for type 2 diabetes patients.
• European guidelines advocate for blood pressure reduction in type 2 diabetes to mitigate cardiovascular events.

Purpose of the Study:

• To assess the efficacy of routine blood pressure lowering using a fixed perindopril/indapamide combination in type 2 diabetes patients.
• To determine if benefits exceed those from background angiotensin-converting enzyme inhibitor therapy.

Main Methods:

• The Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial involved 11,140 patients.
• Investigated the impact of perindopril/indapamide on blood pressure, mortality, and vascular outcomes across diverse baseline blood pressure levels.

Main Results:

• Perindopril/indapamide significantly reduced blood pressure, leading to clinical benefits in type 2 diabetes patients regardless of baseline values.
• Improvements in mortality and vascular outcomes were observed beyond existing antihypertensive therapies.
• Benefits were noted even in normotensive patients, suggesting vascular risk is a crucial factor.

Conclusions:

• Aggressive blood pressure reduction with perindopril/indapamide is beneficial for type 2 diabetes patients, impacting mortality and vascular complications.
• Treatment protocols for type 2 diabetes should consider overall vascular risk, not just initial blood pressure levels, especially for normotensive patients.